Cargando…
A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study
INTRODUCTION: The gut microbiota influences and interacts with the host metabolism through effects on nutrient metabolism and digestion. Duodenal Mucosal Resurfacing (DMR) is a novel endoscopic procedure involving duodenal mucosal ablation by the use of hydrothermal energy. DMR, when combined with a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012157/ https://www.ncbi.nlm.nih.gov/pubmed/36992788 http://dx.doi.org/10.3389/fcdhc.2022.856661 |
_version_ | 1784906561822392320 |
---|---|
author | Meiring, Suzanne van Baar, Annieke C. G. Sørensen, Nikolaj Holleman, Frits Soeters, Maarten R. Nieuwdorp, Max Bergman, Jacques J. G. H. M. |
author_facet | Meiring, Suzanne van Baar, Annieke C. G. Sørensen, Nikolaj Holleman, Frits Soeters, Maarten R. Nieuwdorp, Max Bergman, Jacques J. G. H. M. |
author_sort | Meiring, Suzanne |
collection | PubMed |
description | INTRODUCTION: The gut microbiota influences and interacts with the host metabolism through effects on nutrient metabolism and digestion. Duodenal Mucosal Resurfacing (DMR) is a novel endoscopic procedure involving duodenal mucosal ablation by the use of hydrothermal energy. DMR, when combined with a glucagon-like peptide-1 receptor agonist (GLP-1RA), resulted in discontinuation of exogenous insulin treatment in 69% of patients with insulin dependent type 2 diabetes mellitus (T2DM) in the INSPIRE study. These patients also experienced improved glycaemic control and metabolic health. We thus investigated if these clinical effects were associated with a change in gut microbiota alpha and beta diversity. METHODS: Faecal samples from the 16 patients were obtained for Illumina shotgun sequencing at baseline and 3 months after DMR. We assessed alpha and beta diversity of the gut microbiota in these samples and analysed its correlations with changes in HbA1c, body weight, and liver MRI proton density fat fraction (PDFF). RESULTS: HbA1c correlated negatively with alpha diversity (p=0.011, rho: -0.62) whereas changes in PDFF correlated significantly with beta diversity (p=0.036, rho: 0.55) 3 months after initiation of the combined intervention. These correlations with metabolic parameters were observed despite finding no change in gut microbiota diversity at 3 months post DMR. DISCUSSION: The correlation between gut microbiota richness (alpha diversity) and HbA1c as well as the change in PDFF and changed microbiota composition (beta diversity) suggests that changed gut microbiota diversity is associated with metabolic improvements after DMR in combination with glucagon-like-peptide-1 receptor agonist in type 2 diabetes. Larger controlled studies are however needed to find causal links between DMR with GLP-1RA, the gut microbiota, and improvements in metabolic health. |
format | Online Article Text |
id | pubmed-10012157 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100121572023-03-28 A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study Meiring, Suzanne van Baar, Annieke C. G. Sørensen, Nikolaj Holleman, Frits Soeters, Maarten R. Nieuwdorp, Max Bergman, Jacques J. G. H. M. Front Clin Diabetes Healthc Clinical Diabetes and Healthcare INTRODUCTION: The gut microbiota influences and interacts with the host metabolism through effects on nutrient metabolism and digestion. Duodenal Mucosal Resurfacing (DMR) is a novel endoscopic procedure involving duodenal mucosal ablation by the use of hydrothermal energy. DMR, when combined with a glucagon-like peptide-1 receptor agonist (GLP-1RA), resulted in discontinuation of exogenous insulin treatment in 69% of patients with insulin dependent type 2 diabetes mellitus (T2DM) in the INSPIRE study. These patients also experienced improved glycaemic control and metabolic health. We thus investigated if these clinical effects were associated with a change in gut microbiota alpha and beta diversity. METHODS: Faecal samples from the 16 patients were obtained for Illumina shotgun sequencing at baseline and 3 months after DMR. We assessed alpha and beta diversity of the gut microbiota in these samples and analysed its correlations with changes in HbA1c, body weight, and liver MRI proton density fat fraction (PDFF). RESULTS: HbA1c correlated negatively with alpha diversity (p=0.011, rho: -0.62) whereas changes in PDFF correlated significantly with beta diversity (p=0.036, rho: 0.55) 3 months after initiation of the combined intervention. These correlations with metabolic parameters were observed despite finding no change in gut microbiota diversity at 3 months post DMR. DISCUSSION: The correlation between gut microbiota richness (alpha diversity) and HbA1c as well as the change in PDFF and changed microbiota composition (beta diversity) suggests that changed gut microbiota diversity is associated with metabolic improvements after DMR in combination with glucagon-like-peptide-1 receptor agonist in type 2 diabetes. Larger controlled studies are however needed to find causal links between DMR with GLP-1RA, the gut microbiota, and improvements in metabolic health. Frontiers Media S.A. 2022-07-05 /pmc/articles/PMC10012157/ /pubmed/36992788 http://dx.doi.org/10.3389/fcdhc.2022.856661 Text en Copyright © 2022 Meiring, van Baar, Sørensen, Holleman, Soeters, Nieuwdorp and Bergman https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Clinical Diabetes and Healthcare Meiring, Suzanne van Baar, Annieke C. G. Sørensen, Nikolaj Holleman, Frits Soeters, Maarten R. Nieuwdorp, Max Bergman, Jacques J. G. H. M. A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study |
title | A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study |
title_full | A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study |
title_fullStr | A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study |
title_full_unstemmed | A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study |
title_short | A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study |
title_sort | changed gut microbiota diversity is associated with metabolic improvements after duodenal mucosal resurfacing with glucagon-like-peptide-1 receptor agonist in type 2 diabetes in a pilot study |
topic | Clinical Diabetes and Healthcare |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012157/ https://www.ncbi.nlm.nih.gov/pubmed/36992788 http://dx.doi.org/10.3389/fcdhc.2022.856661 |
work_keys_str_mv | AT meiringsuzanne achangedgutmicrobiotadiversityisassociatedwithmetabolicimprovementsafterduodenalmucosalresurfacingwithglucagonlikepeptide1receptoragonistintype2diabetesinapilotstudy AT vanbaaranniekecg achangedgutmicrobiotadiversityisassociatedwithmetabolicimprovementsafterduodenalmucosalresurfacingwithglucagonlikepeptide1receptoragonistintype2diabetesinapilotstudy AT sørensennikolaj achangedgutmicrobiotadiversityisassociatedwithmetabolicimprovementsafterduodenalmucosalresurfacingwithglucagonlikepeptide1receptoragonistintype2diabetesinapilotstudy AT hollemanfrits achangedgutmicrobiotadiversityisassociatedwithmetabolicimprovementsafterduodenalmucosalresurfacingwithglucagonlikepeptide1receptoragonistintype2diabetesinapilotstudy AT soetersmaartenr achangedgutmicrobiotadiversityisassociatedwithmetabolicimprovementsafterduodenalmucosalresurfacingwithglucagonlikepeptide1receptoragonistintype2diabetesinapilotstudy AT nieuwdorpmax achangedgutmicrobiotadiversityisassociatedwithmetabolicimprovementsafterduodenalmucosalresurfacingwithglucagonlikepeptide1receptoragonistintype2diabetesinapilotstudy AT bergmanjacquesjghm achangedgutmicrobiotadiversityisassociatedwithmetabolicimprovementsafterduodenalmucosalresurfacingwithglucagonlikepeptide1receptoragonistintype2diabetesinapilotstudy AT meiringsuzanne changedgutmicrobiotadiversityisassociatedwithmetabolicimprovementsafterduodenalmucosalresurfacingwithglucagonlikepeptide1receptoragonistintype2diabetesinapilotstudy AT vanbaaranniekecg changedgutmicrobiotadiversityisassociatedwithmetabolicimprovementsafterduodenalmucosalresurfacingwithglucagonlikepeptide1receptoragonistintype2diabetesinapilotstudy AT sørensennikolaj changedgutmicrobiotadiversityisassociatedwithmetabolicimprovementsafterduodenalmucosalresurfacingwithglucagonlikepeptide1receptoragonistintype2diabetesinapilotstudy AT hollemanfrits changedgutmicrobiotadiversityisassociatedwithmetabolicimprovementsafterduodenalmucosalresurfacingwithglucagonlikepeptide1receptoragonistintype2diabetesinapilotstudy AT soetersmaartenr changedgutmicrobiotadiversityisassociatedwithmetabolicimprovementsafterduodenalmucosalresurfacingwithglucagonlikepeptide1receptoragonistintype2diabetesinapilotstudy AT nieuwdorpmax changedgutmicrobiotadiversityisassociatedwithmetabolicimprovementsafterduodenalmucosalresurfacingwithglucagonlikepeptide1receptoragonistintype2diabetesinapilotstudy AT bergmanjacquesjghm changedgutmicrobiotadiversityisassociatedwithmetabolicimprovementsafterduodenalmucosalresurfacingwithglucagonlikepeptide1receptoragonistintype2diabetesinapilotstudy |